

June 15, 2026

Dear Members of the Senate Health, Education, Labor and Pensions Committee,

On behalf of The ERISA Industry Committee (ERIC), we urge you to vote YES on legislation expected to be considered by the Committee that will eliminate unnecessary barriers and bring lower cost drug therapies such as biosimilars to market. **Specifically, we strongly support and urge you to vote in favor of the Medication Affordability and Patent Integrity Act (S. 2658), the Ensuring Timely Access to Generics Act of 2025 (S.3014) and the Biosimilar Red Tape Elimination Act (S. 1954).** These bills will allow for better alignment of filings with the Food and Drug Administration (FDA) and the U.S. Patent and Trademark Office (USPTO) by sponsors of new drug applications and biologics license applications, allow the FDA to deny a citizen petition if it determines the petition was submitted with the primary purpose of delaying the approval of a follow-on generic or biosimilar application, or if the petition does not raise valid scientific or regulatory issues, and removes certain requirements for biosimilars to be designated as interchangeable, respectively.

ERIC is a national nonprofit organization exclusively representing the largest employers in the United States in their capacity as sponsors of employee benefit plans for their nationwide workforces. With member companies that are leaders in every economic sector, ERIC is the voice of large employer plan sponsors on federal, state, and local public policies impacting their ability to sponsor benefit plans and to lawfully operate under ERISA's protection from a patchwork of different and conflicting state and local laws, in addition to federal law.

ERIC applauds the Committee's bipartisan work to address anticompetitive practices that are driving up health care prices and adding to increased premiums and out-of-pocket costs for patients. Importantly, S. 2658, S. 3014, and S. 1954 will help provide quicker access to cheaper drug therapies such as biosimilars and generics, in line with Congressional intent as passed into law in the Hatch-Waxman Act and the Biologic Price Competition and Innovation Act. Such access will provide the 160 million Americans who receive health care coverage through employer-sponsored insurance and their employers some relief from the ever-rising costs of care.

ERIC urges Committee members to vote YES and support the passage of these bills.

Sincerely,

